| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | SAGE THERAPEUTICS | 11,681,008 | 367,952,000 | 42.92% | ||
| 2 | AGIOS PHARMACEUTICALS INC | 3,070,090 | 188,350,000 | 21.97% | ||
| 3 | ZAFGEN INC COM | 5,602,045 | 110,080,000 | 12.84% | ||
| 4 | FOUNDATION MEDICINE INC COM | 4,927,234 | 93,420,000 | 10.90% | ||
| 5 | ELEVEN BIOTHERAPEUTICS INC | 4,841,591 | 53,935,000 | 6.29% | ||
| 6 | BLUEBIRD BIO INCORPORATED | 1,215,054 | 43,596,000 | 5.09% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0001600135-14-000005, filed 2014.10.22).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
